Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed CFO
Quarterly results
Appointed director
GALECTIN THERAPEUTICS INC (GALT) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "NORCROSS, Georgia, August 14, 2023 –"
05/15/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "NORCROSS, Georgia, May 15, 2023 –"
03/30/2023 8-K Quarterly results
03/02/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "NORCROSS, Ga., March 2, 2023"
01/05/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
12/06/2022 8-K Quarterly results
12/01/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
10/12/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer NORCROSS, Ga., October 12, 2022"
10/06/2022 8-K Quarterly results
08/15/2022 8-K Quarterly results
07/26/2022 8-K Amended existing or entered into new employment agreement with an officer
Docs: "Form of Warrant",
"Line of Credit Letter Agreement, by and between Richard E. Uihlein and the Company",
"Form of Convertible Promissory Note",
"Employment Amendment",
"2023 Deferred Stock Unit Agreement",
"2020 Deferred Stock Unit Amendment",
"NORCROSS, Ga., July 26, 2022"
05/16/2022 8-K Quarterly results
04/14/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitoring Board for NAVIGATE,"
03/31/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "NORCROSS, Ga., March 31, 2022"
12/21/2021 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Unsecured Convertible Promissory Note",
"Galectin Therapeutics Announces Closing of $10 Million in Debt Financing from Its Chairman, Richard E. Uihlein"
12/07/2021 8-K Quarterly results
12/03/2021 8-K Quarterly results
11/15/2021 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "NORCROSS, Ga., November 15, 2021 – Galectin"
09/21/2021 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Loan Agreement",
"Unsecured Convertible Promissory Note",
"Galectin Therapeutics Announces $20 Million Convertible Debt Financing from Its Chairman, Richard E. Uihlein"
09/13/2021 8-K Quarterly results
08/16/2021 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "FORM 8-K",
"Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2021, and Provides Business Update"
07/26/2021 8-K Quarterly results
07/09/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "FORM 8-K",
"Galectin Therapeutics Announces Positive Top-Line Results from a Phase 1b Clinical Trial Extension of Belapectin in Combination with KEYTRUDA ® in Advanced Metastatic Melanoma and Head and Neck Cancer"
05/17/2021 8-K Quarterly results
04/19/2021 8-K Quarterly results
03/31/2021 8-K Quarterly results
03/09/2021 8-K Quarterly results
12/07/2020 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
12/03/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Transcript of presentation, December 3, 2020",
"Transcript of presentation, December 3, 2020"
11/09/2020 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "FORM 8-K",
"Galectin Therapeutics Provides Business Update And Reports Financial Results for the Quarter Ended September 30, 2020 Innovative Phase 2b/3 NASH-RX Trial in NASH Cirrhosis Initiated Board Member Joel Lewis Assumes CEO Role - Board Adds Two New Highly Accomplished Professionals"
09/29/2020 8-K Quarterly results
09/22/2020 8-K Quarterly results
09/02/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy